Cipla ties up with Roche to sell 2 cancer drugs in India

The pharma major will distribute Tocilizumab and Syndyma -- the second brand of Roche's cancer therapy bevacizumab -- in India.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news

Related Links:

The phosphoinositide 3-kinase (PI3K) signaling pathway is frequently activated in human cancer due to activating mutations in PI3Ks or the loss of phosphatase and tensin homologue (PTEN) function. In addition to its canonical role as a regulator of cellular proliferation and survival, the PI3K pathway has been implicated in promoting resistance to immune-based anti-cancer therapies. To further define how PI3K signaling may promote tumor cell immune escape, we examined the impact of PI3K inhibition and activation on the induction of MHC class I (MHCI) and II (MHCII) molecules by interferon-gamma (IFN-g).
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Carcinogenesis and Cancer Genetics Source Type: research
When a prostate cancer staging exam is needed, clinicians at one Australian...Read more on AuntMinnie.comRelated Reading: Ga-68 PSMA-11 PET/MRI improves prostate cancer detection Ga-68 PSMA-11 PET/MRI benefits prostate cancer patients Ga-68 PSMA-11 PET/MRI advances prostate cancer detection Gallium-labeled PET tracer could advance cancer detection SNMMI: Early prostate cancer therapy extends lives
Source: Headlines - Category: Radiology Source Type: news
In this study, three PEGylated acid-sensitive prodrugs DOX-PEG-DOX with different molecular weights, were prepared via Schiff-base reaction between aldehyde-modified PEG and the amino groups of doxorubicin (DOX). This kind of amphiphilic polymeric prodrug could be self-assemble into nanoparticles in aqueous solution. The average particle size and morphologies of the prodrug nanoparticles under different pH conditions were observed by dynamic light scattering (DLS) and transmission electron microscopy (TEM), respectively. It turned out that the nanoparticles could be kept stable in the physiological environment, but degrade...
Source: Chinese Chemical Letters - Category: Chemistry Source Type: research
(Medical College of Georgia at Augusta University) Identifying a protein that plays a key role in cancer cell growth is a first step toward the development of a targeted cancer therapy. It is especially promising when this protein is dispensable for the growth of normal cells. Their discovery that UNC45A fits these criteria has researchers, led by Dr. Ahmed Chadli, of the Georgia Cancer Center at Augusta University, excited about potential new cancer therapeutic strategies involving the inhibition of UNC45A.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
In conclusion, our study provides a protocol of producing a biologically active survivin-targeting macromolecule, T34A-C84A-dNSur-His, which can be used as a tool for studying the molecular and cellular roles of survivin in cells. T34A-C84A-dNSur-His is also a potential therapeutic agent for augmenting cancer therapy.
Source: Protein Expression and Purification - Category: Biochemistry Source Type: research
iva Isocitrate dehydrogenases (IDHs) are enzymes that catalyze the oxidative decarboxylation of isocitrate, producing α-ketoglutarate (αKG) and CO2. The discovery of IDH1 and IDH2 mutations in several malignancies has brought to the approval of drugs targeting IDH1/2 mutants in cancers. Here, we summarized findings addressing the impact of IDH mutants in rare pathologies and focused on the relevance of non-mutated IDH enzymes in tumors. Several pieces of evidence suggest that the enzymatic inhibition of IDHs may have therapeutic potentials also in wild-type IDH cancers. Moreover, IDHs inhibition cou...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
A genetic study links cancer-therapy-induced and dilated cardiomyopathies and signals how identification of genetic risk factors may help change management of those at risk.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news
A genetic study links cancer-therapy-induced and dilated cardiomyopathies and signals how identification of genetic risk factors may help change management of those at risk.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news
Cancer cells are characterized by aberrant activation of lipid biosynthesis, producing saturated fatty acids and monounsaturated fatty acids via stearoyl-CoA desaturases (SCD) for regulating metabolic and sign...
Source: Cancer Cell International - Category: Cancer & Oncology Authors: Tags: Primary research Source Type: research
A microfluidic single ‐cell assay for screening therapeutic agents specific to cancer stem cells provides new tools for individualized cancer therapy. AbstractScreens of cancer stem cells (CSCs) ‐specific agents present significant challenges to conventional cell assays due to the difficulty in preparing CSCs ready for drug testing. To overcome this limitation, developed is a microfluidic single‐cell assay for screening breast cancer stem cell–specific agents. This assay takes advanta ge of the single‐cell clone‐forming capability of CSCs, which can be specifically inhibited by CSC‐targeting agents. The s...
Source: Small - Category: Nanotechnology Authors: Tags: Full Paper Source Type: research
More News: Actemra | Avastin | Biotechnology | Cancer | Cancer & Oncology | Cancer Therapy | India Health | Pharmaceuticals